Gilead Sciences in US investigation

Gilead Sciences has received a subpoena from the US Attorney's Office for the Northern District of California requesting documents related to the manufacture, and related quality and distribution practices of its HIV and hepatitis B drugs.

The subpoena involves the drugs Atripla (efavirenz tenofovir emtricitabine), Emtriva (emtricitabine), Hepsera (adefovir dipivoxil), Letairis (ambrisentan), Truvada (tenofovir emtricitabine), Viread (tenofovir) and its investigational fixed-dose combination of Truvada and Edurant (rilpivirine).

In a statement the company said it is cooperating with the civil and criminal investigation.

The case could take years to resolve and is likely to result in a substantial fine.